Reporting
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreReporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreOngoing
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreStart-up
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Learn MoreCompleted
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
Learn MoreCompleted
PCIRN evaluation of pandemic H1N1 (2009) influenza vaccine in adults with human immunodeficiency virus infection: Trial results
Learn MoreCompleted
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
Learn MoreCompleted
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Learn MoreCompleted
Immunogenicity and efficacy study of Fluviral® influenza vaccine strategies in HIV infected Adults: Trial results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
